Cadrenal Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Cadrenal Therapeutics, Inc. (CVKD) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$1.62 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-13
- Cadrenal Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$1.70M.
- Cadrenal Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$2.68M.
- Cadrenal Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$1.84M, a 145.95% decline year-over-year.
- Cadrenal Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $4.00M.
- Cadrenal Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$6.01M, a 472.04% decline from fiscal 2024.
- Cadrenal Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $1.62M, a 80.70% decline from fiscal 2023.
- Cadrenal Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $8.37M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 2 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 5 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 8 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 11 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.62M 10-Q · filed 2026-08-13 | |||||||
| 2026-03-31 | -$1.70M 10-Q · filed 2026-05-07 | |||||||
| 2025-12-31 | -$6.01M 10-K · filed 2026-03-31 | |||||||
| 2025-09-30 | -$6.16M 10-Q · filed 2025-11-10 | |||||||
| 2025-06-30 | -$4.45M 10-Q · filed 2026-08-13 | |||||||
| 2025-03-31 | -$2.68M 10-Q · filed 2026-05-07 | |||||||
| 2024-12-31 | $1.62M 10-K · filed 2026-03-31 | |||||||
| 2024-09-30 | -$4.04M 10-Q · filed 2025-11-10 | |||||||
| 2024-06-30 | -$3.37M 10-Q · filed 2025-08-11 | |||||||
| 2024-03-31 | -$1.84M 10-Q · filed 2025-05-08 | |||||||
| 2023-12-31 | $8.37M 10-K · filed 2025-03-13 | |||||||
| 2023-09-30 | $9.08M 10-Q · filed 2024-11-07 | |||||||
| 2023-06-30 | $3.20M 10-Q · filed 2024-08-07 | |||||||
| 2023-03-31 | $4.00M 10-Q · filed 2024-05-09 | |||||||
| 2022-12-31 | $32.59K 10-K · filed 2024-03-11 | |||||||
| 2022-09-30 | $103.08K 10-Q · filed 2023-11-09 | |||||||
| 2022-06-30 | $59.65K 10-Q · filed 2023-08-10 | |||||||
| 2022-03-31 | $462.34K 10-Q · filed 2023-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B |